More news
Meet our CEO and learn more about our groundbreaking antibody technology and investment opportunity in one of our four investor ...
BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) and Mesenkia Therapeutics announced today that the companies have signed a research collaboration ...
Researchers have identified HVEM as a promising therapeutic target in mesenchymal glioblastoma...
